Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HOOKIPA PHARMA INC.

(HOOK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/26/2021 11/29/2021 11/30/2021 12/01/2021 12/02/2021 Date
3.26(c) 3.22(c) 3.23(c) 3.08(c) 3.14(c) Last
159 165 155 474 955 127 156 523 188 434 Volume
-6.32% -1.23% +0.31% -4.64% +1.95% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 18,7 M - -
Net income 2021 -76,1 M - -
Net cash position 2021 89,9 M - -
P/E ratio 2021 -1,36x
Yield 2021 -
Sales 2022 15,2 M - -
Net income 2022 -90,5 M - -
Net cash position 2022 105 M - -
P/E ratio 2022 -1,35x
Yield 2022 -
Capitalization 94,1 M 94,1 M -
EV / Sales 2021 0,23x
EV / Sales 2022 -0,74x
Nbr of Employees 123
Free-Float 78,9%
More Financials
Company
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company develops immunotherapeutics based on its arenavirus platform that are designed to target and amplify a T cell and immune response to disease. The Company's infectious and oncology product candidates HB-101, HB-201, HB-202 and HB-300. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical... 
Sector
Pharmaceuticals
Calendar
03/24Earnings Release
More about the company
Ratings of HOOKIPA Pharma Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about HOOKIPA PHARMA INC.
11/12HOOKIPA Pharma to Participate in Upcoming Stifel 2021 Virtual Healthcare Conference
AQ
11/12Morgan Stanley Downgrades HOOKIPA Pharma to Equal-Weight From Overweight; Price Target ..
MT
11/11HC Wainwright Adjusts Price Target on Hookipa Pharma to $15 From $21, Keeps Buy Rating
MT
11/11HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights
AQ
11/10SVB Leerink Adjusts HOOKIPA Pharma PT to $10 From $28, Maintains Outperform Rating
MT
11/10JMP Securities Adjusts Price Target on HOOKIPA Pharma to $11 From $25, Maintains Market..
MT
11/10RBC Cuts PT on HOOKIPA Pharma to $17 From $24, Citing Program Prioritization, Timeline ..
MT
11/10HOOKIPA PHARMA INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
11/10HOOKIPA Pharma Reports Third Quarter 2021 Financial Results andRecent Highlights - Form..
PU
11/10HOOKIPA Pharma Reports Third Quarter 2021 Financial Results andáRecent Highlights
GL
11/09HOOKIPA advances HB-200 program to Phase 2 and prioritizes oncology portfolio based on ..
PU
11/09HOOKIPA PHARMA INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exh..
AQ
11/09HOOKIPA advances HB-200 program to Phase 2 and prioritizes oncology portfolio based on ..
GL
11/09HOOKIPA Pharma Inc. Advances HB-200 Program to Phase 2 and Prioritizes Oncology Portfol..
CI
10/14HOOKIPA PHARMA : announces publication on the benefits of its novel arenaviral immunothera..
AQ
More news
News in other languages on HOOKIPA PHARMA INC.

- No features available -

More news
Analyst Recommendations on HOOKIPA PHARMA INC.
More recommendations
Chart HOOKIPA PHARMA INC.
Duration : Period :
HOOKIPA Pharma Inc. Technical Analysis Chart | HOOK | US43906K1007 | MarketScreener
Technical analysis trends HOOKIPA PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,14 $
Average target price 14,14 $
Spread / Average Target 350%
EPS Revisions
Managers and Directors
J÷rn Aldag Chief Executive Officer & Director
Thomas Lingelbach President
Reinhard Kandera Chief Financial Officer & Director
Jan G. J. van de Winkel Chairman
Igor Matushansky Chief Medical Officer & Global Head-Research
Sector and Competitors
1st jan.Capi. (M$)
HOOKIPA PHARMA INC.-72.23%92
JOHNSON & JOHNSON0.44%416 161
ROCHE HOLDING AG18.38%343 323
PFIZER, INC.48.55%306 912
NOVO NORDISK A/S66.91%247 444
ELI LILLY AND COMPANY47.55%225 859